Psoriasis
Conditions
Keywords
quality of life, psychotherapy, psoriasis, treatments
Brief summary
The aim of this study is to determine the benefits of individual psychotherapy on quality of life for people with psoriasis receiving medical treatment versus a control group (awaiting group) treated with medical treatment, without psychotherapy.
Detailed description
Further investigations studies are needed to determine the efficacy of psychological interventions for people with psoriasis. The aim of this study is to determine the benefits of individual psychotherapy on quality of life for people with psoriasis receiving medical treatment versus a control group (awaiting group) treated with medical treatment, without psychotherapy. This is an experimental randomized trial with control group. Quality of life, symptoms: pruritus, scaling and pain, distress and the illness will be measured before and after the intervention using psychological and quality of life questionnaires, and dermatological evaluations for 120 subjects. The investigators expect that the experimental group scores at the end of the psychotherapy program will be less than 4 points in Visual Analog Scale (VAS) for pruritus, scaling and pain. The Dermatology Quality of Life Index (DQLI) expected to be less than 4 points from the initial score, and the patients are expected to present less than 7 points in Hospital Anxiety and Depression Scale (HADS). The experimental group scores will be less than the control group for quality of life, symptoms and distress.
Interventions
BEHAVIORALPsychotherapy
Individual psychotherapy
Sponsors
Universitat Autonoma de Barcelona
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women at least 18 years old at the time of selection. * Subjects diagnosed with moderated or severe psoriasis. * Subjects with a ≥ 10 punctuation in DLQI questionnaire. * Subjects that are in dermatological treatment. * Patients should be able to understand and communicate with the investigator.
Exclusion criteria
* Subjects suffering from a serious concomitant illness. * Subjects with a mental illness. * Subjects who are performing psychiatric treatment. * Subjects who are performing psychotherapy sessions both individual and group. * Patients who have alcohol dependence or drug abuse. * Subjects that present legal incapacity or limited legal capacity. * Subjects presenting illiteracy or language barriers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dermatology Quality of Life Index (DLQI) | 1 year | The Dermatology Life Quality Index or DLQI, developed in 1994, was the first dermatology-specific Quality of Life instrument. It is a simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages. Its use has been described in over 1000 publications including many multinational studies. The DLQI is the most frequently used instrument in studies of randomised controlled trials in dermatology. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual analog scale (VAS) for pain | 1 year | A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. Operationally a VAS is usually a horizontal line, 100 mm in length. The patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks. |
| Visual analog scale (VAS) for scaling | 1 year | A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. Operationally a VAS is usually a horizontal line, 100 mm in length. The patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks. |
| Hospital Anxiety and Depression Scale (HADS) | 1 year | Hospital Anxiety and Depression Scale (HADS) was originally developed by Zigmond and Snaith (1983) and is commonly used by doctors to determine the levels of anxiety and depression that a patient is experiencing. The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. |
| Visual analog scale (VAS) for pruritus | 1 year | A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. Operationally a VAS is usually a horizontal line, 100 mm in length. The patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks. |
| Static Physician's Global Assessment (sPGA) | 1 year | The PGA is a 5 point ordinal rating ranging from clear to very severe psoriasis. |
| Body surface area (BSA) | 1 year | The Body surface area is defined as 9% coverage for the head and neck, each arm, anterior and posterior leg as well as the four trunk quadrants respectively, leaving 1% for the genitalia. The BSA can also be estimated by the number of patients' hand areas affected, assuming that one handprint reflects approximately 1% of BSA |
| Psoriasis Area Severity Index (PASI) | 1 year | The Psoriasis Area Severity Index (PASI) is an index used to express the severity of psoriasis. It combines the severity (erythema, induration and desquamation) and percentage of affected area. |
Countries
Spain
Contacts
Primary ContactEsther Margarit de Miguel, Msc
Backup ContactEva Vilarrasa, Dr
Outcome results
None listed